T3D
0.05
233.3%
PEN
0.33
-46.8%
GML
0.045
60.7%
RGL
0.003
-40%
ENT
0.008
60%
KLR
0.54
-34.1%
AIV
0.02
53.8%
JAV
0.002
-33.3%
QXR
0.006
50%
M2R
0.002
-33.3%
AQI
0.038
35.7%
RDS
0.004
-33.3%
NPM
0.018
28.6%
AOA
0.003
-25%
AHK
0.455
28.2%
BLZ
0.003
-25%
VML
0.165
26.9%
MEM
0.003
-25%
FIN
0.005
25%
LEG
0.007
-22.2%
VRC
0.005
25%
ADG
0.004
-20%
BCM
0.023
21.1%
CAV
0.004
-20%
FL1
0.12
20%
CVB
0.14
-20%
WHK
0.012
20%
FBR
0.004
-20%
S66
0.195
18.2%
IMI
0.008
-20%
KLS
4.76
18.1%
TRM
0.042
-19.2%
PAT
0.04
17.6%
GBE
0.06
-16.7%
NXL
2.41
17%
XGL
0.02
-16.7%
AJX
0.007
16.7%
ATV
0.016
-15.8%
AVE
0.007
16.7%
LU7
0.011
-15.4%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

LTR Pharma (ASX:LTP) has listed on the ASX

LTR Pharma (ASX:LTP) has listed on the ASX with a ticker code of LTP. The company is a clinical stage biopharmaceutical company and pioneering a novel intranasal technology – SPONTAN® – designed to treat erectile dysfunction in 10 minutes or less. LTR Pharma says the benefit of its business model is a significantly reduced time to approval and lower cost, even when compared with traditional drug repurposing strategies. The global erectile dysfunction market is expected to generate revenue of more than $7 billion US dollars by the end of 2026 | Investor presentation: https://lnkd.in/gb3b5T3j #LTP #ASX #ASXstocks #stocks #ASXIPO ##LTRPharma #ED #erectiledysfunction #shorts